Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Archives of General Psychiatry|April 1, 1996
Incidence and correlates of tardive dyskinesia in first episode of schizophreniaM H Chakos, J M Alvir, M G Woerner, et al.
Acta Psychiatrica Scandinavica|February 13, 2018
Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophreniaB Galling, J A Vernon, A K Pagsberg, et al.
The Pharmacogenomics Journal|May 20, 2009
Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophreniaB A Fijal, B J Kinon, S Kapur, et al.
Epilepsy Research|April 1, 1997
Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective propertiesJ H Kehne, J M Kane, S F Chaney, et al.
Brain, Behavior, and Immunity|February 8, 2017
Protection against alcohol-induced neuronal and cognitive damage by the PPARγ receptor agonist pioglitazoneAndrea Cippitelli, Esi Domi, Massimo Ubaldi, et al.
The American Journal of Psychiatry|June 1, 1997
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study GroupD L Zimbroff, J M Kane, C A Tamminga, et al.
Sarcoma|May 24, 2012
Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330J M Kane, J Harris, W G Kraybill, et al.
Archives of General Psychiatry|November 1, 2001
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparisonJ M Kane, S R Marder, N R Schooler, et al.
British Journal of Pharmacology|August 1, 1992
MDL 27,531 selectively reverses strychnine-induced seizures in miceJ H Kehne, J M Kane, F P Miller, et al.
Molecular Psychiatry|March 16, 2005
Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formationP R Szeszko, R Lipsky, C Mentschel, et al.
Pageof 21